Cargando…
Update on the use of aromatase inhibitors in early-stage breast cancer
Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treat...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790854/ https://www.ncbi.nlm.nih.gov/pubmed/19889200 http://dx.doi.org/10.1186/bcr2410 |